GlassScriptPhysician profile
Nicholas H Rice
NPI 1265538235
$1,123.78
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $209 · 2021: $129 · 2022: $162 · 2023: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $235.32 | 2019-2023 | |
| Amgen INC. | $199.86 | 2019-2023 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $83.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $67.35 | 2019-2020 | |
| Novo Nordisk INC | $61.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $43.40 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $42.46 | 2019-2020 | |
| Radius Health, INC. | $39.81 | 2020-2021 | |
| Boston Scientific Corporation | $38.02 | 2019 | |
| Medicure Pharma INC. | $34.28 | 2021 | |
| Scilex Pharmaceuticals INC. | $28.09 | 2019 | |
| Idorsia Pharmaceuticals US INC | $27.76 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.69 | 2020 | |
| Amarin Pharma, INC. | $25.60 | 2020-2021 | |
| Abbvie INC. | $25.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.03 | 2023 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $16.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.43 | 2021 | |
| Ge Healthcare | $14.65 | 2020 | |
| Janssen Biotech, INC. | $14.55 | 2019 | |
| Daiichi Sankyo INC. | $14.32 | 2020 | |
| Glaxosmithkline, LLC. | $13.75 | 2023 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.